NKX019 is an allogeneic, cryopreserved CAR-NK cell product targeting CD19, equipped with CD3zeta and OX40 co-stimulatory domains, and an independent membrane-bound IL-15 for activation. It is derived from natural killer (NK) cells of healthy donors and is being investigated for the treatment of relapsed/refractory B-cell malignancies[1].
Target-Kategorie:
CD19
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
